Search

Displaying results 1941 - 1950 of 10000 in total
  1. Indication

    Degenerative Joint Disease

    go.drugbank.com/conditions/DBCOND0039319
    Drugs: Methylprednisolone
    Synonyms: O/A
  2. Indication

    Sezary Syndrome

    go.drugbank.com/conditions/DBCOND0001518
    Drugs: Doxorubicin · Isotretinoin · Pentostatin
    Synonyms: Cutaneous T-cell lymphoma, no ICD-O subtype
  3. Indication

    Squamous Cell Carcinoma (SCC)

    go.drugbank.com/conditions/DBCOND0043488
    Drugs: Bleomycin
    Synonyms: Squamous cell carcinoma, no ICD-O subtype
  4. Indication

    Splinter

    go.drugbank.com/conditions/DBCOND0015551
    Drugs: Ichthammol
    Synonyms: Splinter in skin (disorder)
  5. Target

    Cytoplasmic tyrosine-protein kinase BMX

    go.drugbank.com/bio_entities/BE0009416
    TargetHumans

    May also play a role in the growth and differentiation of hematopoietic cells; as well as in signal transduction in endocardial and arterial endothelial cells … Plays a critical role in TNF-induced angiogenesis, and implicated in the signaling of TEK and FLT1 receptors, 2 important receptor families essential for angiogenesis.

    Synonyms: Bone marrow tyrosine kinase gene in chromosome X protein
  6. Drug

    Nepidermin

    go.drugbank.com/drugs/DB14145
    Investigational

    Mixtures: EASYDEW DW EGF Derma Oneshot AmpouleCategories: EGF Family of Proteins
  7. Drug

    Glutamic acid

    go.drugbank.com/drugs/DB00142
    ApprovedInvestigationalNutraceutical

    A peptide that is a homopolymer of glutamic acid.

    Mixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), Aminosyn II in DextroseSynonyms: (S)-2-Aminopentanedioic acid, L-Glutamate
  8. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: COTELLIC® (COBIMETINIB) 20 MG TABLETAS RECUBIERTAS
  9. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  10. Target

    Lysocardiolipin acyltransferase 1

    go.drugbank.com/bio_entities/BE0015711
    EnzymeHumans

    Exhibits acyl-CoA:lysocardiolipin acyltransferase (ALCAT) activity; catalyzes the reacylation of lyso-cardiolipin to cardiolipin (CL), a key step in CL remodeling (By similarity).

    Synonyms: 1-acylglycerol-3-phosphate O-acyltransferase 8Function: 1-acylglycerol-3-phosphate O-acyltransferase activity